VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the target virus. It is also developing congenital cytomegalovirus vaccine candidate for infectious disease; and therapeutic glioblastoma multiforme vaccine candidate for immuno-oncology. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. The company is headquartered in Cambridge, Massachusetts. VBI Vaccines Inc. is a subsidiary of FDS Pharma ASS.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-830-3031
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.36 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/7/2019 (Estimated)
OptionableOptionable
VBI Vaccines (NASDAQ:VBIV) Frequently Asked Questions
What is VBI Vaccines' stock symbol?
VBI Vaccines trades on the NASDAQ under the ticker symbol "VBIV."
How were VBI Vaccines' earnings last quarter?
VBI Vaccines Inc (NASDAQ:VBIV) posted its quarterly earnings data on Monday, February, 25th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by $0.09. VBI Vaccines had a negative net margin of 1,895.74% and a negative return on equity of 68.48%. View VBI Vaccines' Earnings History.
When is VBI Vaccines' next earnings date?
What price target have analysts set for VBIV?
3 equities research analysts have issued twelve-month target prices for VBI Vaccines' stock. Their predictions range from $9.00 to $12.00. On average, they anticipate VBI Vaccines' share price to reach $10.50 in the next year. This suggests a possible upside of 433.0% from the stock's current price. View Analyst Price Targets for VBI Vaccines.
What is the consensus analysts' recommendation for VBI Vaccines?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VBI Vaccines in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for VBI Vaccines.
Has VBI Vaccines been receiving favorable news coverage?
News stories about VBIV stock have trended somewhat negative this week, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. VBI Vaccines earned a daily sentiment score of -1.5 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days.
Are investors shorting VBI Vaccines?
VBI Vaccines saw a decline in short interest in the month of February. As of February 15th, there was short interest totalling 981,006 shares, a decline of 43.6% from the January 31st total of 1,739,334 shares. Based on an average daily volume of 296,416 shares, the days-to-cover ratio is currently 3.3 days. Currently, 1.3% of the shares of the company are sold short. View VBI Vaccines' Current Options Chain.
Who are some of VBI Vaccines' key competitors?
Some companies that are related to VBI Vaccines include CymaBay Therapeutics (CBAY), ANI Pharmaceuticals (ANIP), Cara Therapeutics (CARA), ZIOPHARM Oncology (ZIOP), Eagle Pharmaceuticals (EGRX), Revance Therapeutics (RVNC), Evolus (EOLS), Vectura Group (VEGPF), Viking Therapeutics (VKTX), Intra-Cellular Therapies (ITCI), TG Therapeutics (TGTX), Synthorx (THOR), Aurinia Pharmaceuticals (AUPH), Magenta Therapeutics (MGTA) and Crinetics Pharmaceuticals (CRNX).
What other stocks do shareholders of VBI Vaccines own?
Who are VBI Vaccines' key executives?
VBI Vaccines' management team includes the folowing people:
- Mr. Jeff R. Baxter, CEO, Pres & Director (Age 58)
- Dr. David Evander Anderson, Chief Scientific Officer (Age 49)
- Dr. Francisco Diaz-Mitoma, Chief Medical Officer (Age 64)
- Mr. Christopher McNulty, CFO & Head of Bus. Devel. (Age 42)
- Ms. Athena Kartsaklis, Sr. VP of Fin., Chief Compliance Officer & Principal Financial Officer (Age 54)
Who are VBI Vaccines' major shareholders?
VBI Vaccines' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Perceptive Advisors LLC (26.27%), Menora Mivtachim Holdings LTD. (5.77%), General American Investors Co. Inc. (1.94%), Cambridge Investment Research Advisors Inc. (1.48%), Millennium Management LLC (0.83%) and Fosun International Ltd (0.71%). Company insiders that own VBI Vaccines stock include Francisco Diaz-Mitoma, Jeff Baxter, Life Sciences Maste Perceptive, Nell Beattie, Opko Health, Inc, Perceptive Advisors Llc, Steven Gillis and Tomer Kariv. View Institutional Ownership Trends for VBI Vaccines.
Which institutional investors are selling VBI Vaccines stock?
Which institutional investors are buying VBI Vaccines stock?
VBIV stock was purchased by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Menora Mivtachim Holdings LTD., General American Investors Co. Inc., Fosun International Ltd, Millennium Management LLC, CVI Holdings LLC, Geode Capital Management LLC and Geode Capital Management LLC. Company insiders that have bought VBI Vaccines stock in the last two years include Francisco Diaz-Mitoma, Jeff Baxter, Life Sciences Maste Perceptive, Nell Beattie, Opko Health, Inc, Perceptive Advisors Llc, Steven Gillis and Tomer Kariv. View Insider Buying and Selling for VBI Vaccines.
How do I buy shares of VBI Vaccines?
Shares of VBIV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is VBI Vaccines' stock price today?
One share of VBIV stock can currently be purchased for approximately $1.97.
How big of a company is VBI Vaccines?
VBI Vaccines has a market capitalization of $192.39 million and generates $3.36 million in revenue each year. The biopharmaceutical company earns $-63,600,000.00 in net income (profit) each year or ($0.97) on an earnings per share basis.
What is VBI Vaccines' official website?
How can I contact VBI Vaccines?
VBI Vaccines' mailing address is 222 Third Street Suite 2241, Cambridge MA, 02142. The biopharmaceutical company can be reached via phone at 617-830-3031 or via email at [email protected]
MarketBeat Community Rating for VBI Vaccines (NASDAQ VBIV)
MarketBeat's community ratings are surveys of what our community members think about VBI Vaccines and other stocks. Vote "Outperform" if you believe VBIV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VBIV will underperform the S&P 500 over the long term. You may vote once every thirty days.
